Mr. Alan Rootenberg reports

SEARCHTECH VENTURES INC. FILES FILING STATEMENT FOR PROPOSED QUALIFYING TRANSACTION WITH HORTICAN INC. DBA PHARMACAN

Searchtech Ventures Inc. has filed its filing statement dated Nov. 28, 2014, prepared in accordance with the requirements of the TSX Venture Exchange and relating to its proposed qualifying transaction with Hortican Inc., doing business as PharmaCan, announced on July 17, 2014, with the exchange and the applicable Canadian securities regulators. The filing statement is available under Searchtech's corporate profile on SEDAR.

The proposed qualifying transaction involves the merger of Searchtech and PharmaCan by way of a plan of arrangement involving a three-cornered amalgamation between PharmaCan, Searchtech and a wholly owned subsidiary of Searchtech. All of the issued and outstanding shares of PharmaCan will be acquired on the basis of 2.1339 postconsolidation common shares of Searchtech for each one common share of PharmaCan. Searchtech will also change its name to "PharmaCan Capital Corp." and consolidate its common shares on the basis of one postconsolidation common share for each seven preconsolidation common shares.

Final acceptance of the qualifying transaction by the exchange is subject to the satisfaction of certain conditions, including fulfilment of all the remaining filing requirements under the policies of the exchange. It is anticipated that the qualifying transaction will be completed on Dec. 10, 2014, subject to satisfaction of the exchange conditions.

About PharmaCan

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a licence, to produce medical marijuana pursuant to the Marihuana for Medical Purposes Regulations. The MMPR came into force in October, 2013. As of July 1, 2014, 13 companies are listed on the Heath Canada website as fully licensed to produce and sell medical marijuana. PharmaCan has made investments in several companies that are either licensed or in the process of seeking a licence. In the case of PharmaCan investees that have not yet acquired a licence, additional investment is conditional upon receipt of an MMPR licence being obtained.

We seek Safe Harbor.